Kenneth A. Burdick, a director at LifeStance Health Group, Inc. (NASDAQ:LFST), has sold a substantial block of the company's common stock, according to a filing with the U.S. Securities and Exchange Commission. The transaction, executed on November 16, 2026, involved the disposition of 124,228 shares, generating proceeds of approximately $1,777,702.
The shares were sold at prices ranging from $14.30 to $14.33, with a weighted average price of $14.31 per share. The sale arrives on the heels of a remarkable run for LifeStance stock, which has climbed 123% over the past year and is trading near its 52-week high of $15.66. Year-to-date, the stock has gained 96%, and analysis indicates shares are trading close to Fair Value.
Following this transaction, Burdick directly holds 3,472,038 shares of LifeStance Health Group common stock. In addition, he indirectly beneficially owns 46,511 shares through Burdick Family LLC.
The insider sale comes amid a period of strong operational performance for LifeStance. In its third-quarter 2026 earnings report, the company delivered adjusted earnings of $0.06 per share on revenue of $455.86 million, surpassing Wall Street forecasts of $0.04 per share and $431.6 million in revenue. This marked a 25% increase in revenue from the previous year and the second consecutive quarter of such growth. Adjusted EBITDA also rose 70% to $68 million, maintaining a margin of 15% of revenue.
Encouraged by these results, LifeStance Health raised its full-year outlook for revenue, center margin, and adjusted EBITDA. BMO Capital responded by lifting its price target for LifeStance Health to $16.00 from $13.00, while keeping an Outperform rating. The firm highlighted the company's third-quarter performance, noting that revenue came in 5.6% above consensus estimates and EBITDA surpassed expectations by 23.6%. LifeStance Health's management also increased its full-year revenue and EBITDA outlook by 2.7% and 9.3%, respectively.
The stock closed at $13.77 on November 18, down $0.40 or 2.82%, and edged slightly lower in after-hours trading to $13.76, a decline of $0.01 or 0.07%.
Investors seeking deeper insights into LifeStance Health Group can access comprehensive research reports, which are available for LFST and over 1,400 other US equities.